Coronado Industries to Begin Trading On Hamburg Stock Exchange.

Business Editors and Health Writers

FOUNTAIN HILLS, Ariz.--(BUSINESS WIRE)--March 2, 2000

Coronado Industries, Inc. (OTC BB: CDIK), a manufacturer of proprietary pneumatic devices for the effective treatment of glaucoma, today announced that it will begin trading its common stock on the Hamburg Stock Exchange under its existing trading symbol (CDIK) on March 10, 2000.

On that date, all biotechnology companies trading on the German market will be centralized on the Hamburg Exchange.

Coronado president, Gary Smith, commented, "The listing of our common stock on the Hamburg Exchange is the culmination of a concerted effort by many to move the Company into the European market. Over the past few months, our ability to meet face-to-face with members of the European medical and investment communities strengthened our application for listing on the Hamburg Exchange, while increasing interest in, and support of, our patented Pneumatic Trabeculoplasty device and treatment. We are particularly grateful to our German affiliate, WorldofInternet.com AG, for its assistance in advancing our presence in within the European community."

Smith continued, "With interest in Pneumatic Trabeculoplasty (PNT(tm)) increasing among medical professionals and the member countries of the European Parliament, the ability to offer our stock on a European exchange is crucial to achieving full commercialization of the device, and will serve as an impetus to our continuing efforts to obtain full FDA approval in the United States."

Coronado Industries, through its wholly-owned subsidiaries American Glaucoma and Opthalmic International, focuses on the development and testing of a patented procedure, Pneumatic Trabeculoplasty (PNT(tm)), a non-invasive, highly effective, and low-cost alternative to traditional treatments.

Currently, the Company markets its pneumatic suction device and treatment throughout the European marketplace under a CE Mark (allowing manufacturers to freely sell their products) from the European Commission. Pending FDA approval, the Company will license its patented treatment procedure and equipment in the United States.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.

For additional information, see www.coronadoindustries.com or www.otcfn.com/cdik/4pg.html